• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?

作者信息

Garraud Olivier, Watier Hervé

机构信息

SAINBIOSE INSERM U1049, Université de Saint-Etienne, Saint-Etienne, France.

CPER INSERM U1100 and Université de Tours, and CHRU de Tours, Tours, France.

出版信息

Transfus Apher Sci. 2023 Jun;62(3):103726. doi: 10.1016/j.transci.2023.103726. Epub 2023 May 8.

DOI:10.1016/j.transci.2023.103726
PMID:37169698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10164650/
Abstract
摘要

相似文献

1
Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?是否有恢复使用血浆疗法或中和康复期抗体疗法来治疗新冠病毒变种，我们是否正在重新思考防范计划？
Transfus Apher Sci. 2023 Jun;62(3):103726. doi: 10.1016/j.transci.2023.103726. Epub 2023 May 8.
2
Thinking more about therapy with convalescent plasma for COVID-19 patients.更多地思考针对新冠病毒肺炎患者使用康复期血浆进行治疗的问题。
Hum Vaccin Immunother. 2020 Nov 1;16(11):2601-2603. doi: 10.1080/21645515.2020.1787073. Epub 2020 Jul 9.
3
On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy.关于确定核衣壳抗体的贡献作为 COVID-19 恢复期血浆疗效的潜在贡献的必要性。
Viruses. 2022 Oct 27;14(11):2378. doi: 10.3390/v14112378.
4
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
5
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.病例报告：双滤过血浆置换获得的抗 SARS-CoV-2 恢复期抗体的作用。
Front Immunol. 2021 Jun 30;12:711915. doi: 10.3389/fimmu.2021.711915. eCollection 2021.
6
Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.康复期血浆捐献中ABO血型与抗SARS-CoV-2中和抗体滴度之间的相关性
Transfus Clin Biol. 2022 May;29(2):186-187. doi: 10.1016/j.tracli.2021.10.002. Epub 2021 Oct 12.
7
Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.康复期血浆和超免疫球蛋白针对新冠病毒BQ.1、BQ.1.1和XBB变体的治疗潜力
J Clin Invest. 2023 Apr 17;133(8):e168583. doi: 10.1172/JCI168583.
8
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
9
Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.从 COVID-19 恢复期血浆中开发和表征抗 SARS-CoV-2 静脉用免疫球蛋白。
Immunotherapy. 2022 Oct;14(14):1133-1147. doi: 10.2217/imt-2022-0015. Epub 2022 Jul 27.
10
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.恢复期血浆捐献者在免疫接种后对 SARS-CoV-2 的抗原变异体表现出增强的交叉反应性中和抗体反应。
Transfusion. 2022 Jul;62(7):1347-1354. doi: 10.1111/trf.16934. Epub 2022 Jun 2.

引用本文的文献

1
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review.抗新冠病毒的高效价免疫血浆和免疫球蛋白：叙述性综述
Life (Basel). 2024 Feb 1;14(2):214. doi: 10.3390/life14020214.

本文引用的文献

1
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗：一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.
2
A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.一种能够破坏 Spike 的人源抗体，可有效中和包含奥密克戎在内的 SARS-CoV-2 变异株，并具有治疗效果。
PLoS Pathog. 2023 Jan 27;19(1):e1011085. doi: 10.1371/journal.ppat.1011085. eCollection 2023 Jan.
3
Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study.在 COVID-19 恢复期血浆队列研究中炎症标志物和自身抗 I 型干扰素。
EBioMedicine. 2023 Jan;87:104414. doi: 10.1016/j.ebiom.2022.104414. Epub 2022 Dec 17.
4
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies.基于体外研究的 SARS-CoV-2 变异体对单克隆抗体的逃逸
Nat Rev Microbiol. 2023 Feb;21(2):112-124. doi: 10.1038/s41579-022-00809-7. Epub 2022 Oct 28.
5
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.关注的奥密克戎变异株：刺突蛋白的多样化和趋同进化，以及逃避抗刺突单克隆抗体。
Drug Resist Updat. 2022 Dec;65:100882. doi: 10.1016/j.drup.2022.100882. Epub 2022 Oct 3.
6
Thirty years of hemovigilance - Achievements and future perspectives.三十年的血液监测——成就与未来展望。
Transfus Clin Biol. 2023 Feb;30(1):166-172. doi: 10.1016/j.tracli.2022.09.070. Epub 2022 Oct 8.
7
Early and out-of-hospital use of COVID-19 convalescent plasma: An international assessment of utilization and feasibility.COVID-19 恢复期血浆的早期和院外应用：利用和可行性的国际评估。
Vox Sang. 2022 Oct;117(10):1202-1210. doi: 10.1111/vox.13347. Epub 2022 Sep 14.
8
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma.美国血库协会（AABB）临床实践指南：COVID-19 恢复期血浆。
Ann Intern Med. 2022 Sep;175(9):1310-1321. doi: 10.7326/M22-1079. Epub 2022 Aug 16.
9
Monoclonal antibody therapies against SARS-CoV-2.针对 SARS-CoV-2 的单克隆抗体疗法。
Lancet Infect Dis. 2022 Nov;22(11):e311-e326. doi: 10.1016/S1473-3099(22)00311-5. Epub 2022 Jul 5.
10
Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.用于治疗新冠病毒肺炎的康复期血浆——解读其中的不一致之处
N Engl J Med. 2022 May 5;386(18):1753-1754. doi: 10.1056/NEJMe2204332.